SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 33.23+0.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (13987)7/5/2000 4:33:07 PM
From: Oak Tree  Read Replies (1) of 17367
 
At the risk of being further blasted,
(1) I understand that everyone got two units
(2) I understand that therefore everyone got natural BPI and there was not control arm
(3) I didn't understand that Robert was a BPI believer and thought that the trial failed because there was no true untreated arm. That issue is relevant also.

I guess what some of you might not have understood (and perhaps I didn't make it clear) was that the inhibitor would support the utility of BPI in high dose.

I think it is also relevant to note that the paper suggested that not only was there BPI in blood, patients who got blood did poorly. While this is almost certainly related to the degree of trauma, it does not support an advantage of BPI.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News